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A Case Report of Advanced Neglected Basal Cell Carcinoma 
Abstract 
Background: Basal cell carcinoma is the most common skin cancer in humans and is frequently found in 
the periocular region. It is generally characterized by slow growth with rare metastasis and has an 
excellent prognosis with current surgical techniques. However, if neglected or inadequately treated it can 
lead to substantial localized tissue destruction and morbidity. 
Case Report: This case presents an advanced basal cell carcinoma involving the left side of the nose and 
medial eyelids which had been neglected by the patient, causing significant functional disability and 
cosmetic disfigurement. The tumor was removed with a wide surgical excision which required skin grafts 
and eyelid reconstruction. 
Conclusion: Early diagnosis and management of suspicious lesions is important to ensure the best 
clinical result. In extreme cases psychosocial or economic factors may delay treatment, resulting in more 
aggressive growth which requires more extensive multidisciplinary intervention to achieve a satisfactory 
outcome for the patient. 
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  Basal cell carcinoma (BCC) is the most common periocular malignancy found in 
humans.1,2 While it is usually slow growing and rarely metastasizes, if treatment is 
delayed it can be highly locally invasive and cause destruction of adjacent tissue of 
the eye, orbit, nose, sinuses, and face.  Early recognition and intervention is 
important to minimize local complications and disfigurement, and with appropriate 
management the prognosis is usually good.  This case report describes an advanced 
basal cell carcinoma involving the left side of the nose and eyelids which had been 
neglected by the patient, leading to significant localized growth and disfigurement.  
The tumor was successfully removed with a wide surgical excision requiring skin 




  A 73-year-old male presented for care at the James H. Quillen Veterans Affairs 
Medical Center (VAMC) with a large growth that started in the corner of his left 
eye three years previously.  The patient noted that it had grown rapidly with 
occasional associated purulent drainage and bleeding for at least the past six 
months, and he was having trouble breathing out of the left side of his nose.  His 
history included not having seen a physician for 50 years, although he did see a 
private doctor for this tumor about 4 months before coming to the VA.  The patient 
said he was told it was skin cancer, but he had not gone back for any follow up 
visits.  He was alert and oriented, did not report being on any medications, and was 
not being followed for any systemic conditions.  A plastic surgeon and an Ear, 
Nose, and Throat (ENT) specialist were consulted, and examination described a 
baseball- size fungating, exophytic, necrotic mass approximately 12 cm in diameter 
involving the left side of the nose with collapse of the left nasal airway.  A 
subsequent biopsy diagnosed the tumor as an ulcerated basal cell carcinoma.  
   
  A computed tomography (CT) scan without contrast (the patient declined contrast 
testing) showed extension of the tumor into the left preseptal space and anterior 
medial orbit with involvement of the medial eyelids (Figure 1).  There was 
mucoperiosteal thickening of the left maxillary sinus with preservation of the 
paranasal sinuses, but no associated bony lesion, and no focal lesion of the brain.  
Management options that were initially considered included discussion of a 
rhinectomy with possible exenteration of the orbital contents based on the degree 
of infiltration of the tumor, or a wide surgical excision with radiation therapy.   
 
15
Bennett: Neglected Basal Cell Carcinoma
Published by The Athenaeum, 2021
 
Figure 1:  Axial CT scan without contrast showing a large basal cell carcinoma involving the left 
side of the nose with collapse of the left nasal airway (red arrow), and extension of the tumor into 
the left anterior medial orbit and medial eyelids.  
   
  The patient was then referred to the VAMC Eye Clinic to assess the degree of 
ophthalmic involvement.  A large necrotic mass with an unpleasant odor was 
observed as previously described on the left side of the nose and face, extending 
into the medial canthus and involving the medial left upper and lower eyelids 
(Figure 2).  The patient’s affect seemed depressed; he was alert and oriented, but 
minimally communicative.  He described a lifelong history of decreased vision in 
the right eye, but he hadn’t had an eye exam for several years and had stopped 
wearing glasses because they were not improving his vision.  He did note that his 
left eye had always been his “good eye,” and stated that the vision was getting 
worse, but he did not complain of visual disability.  When questioned as to why he 
did not seek care earlier, he did not provide an answer.  Family members explained 
that he continually refused medical care until the tumor grew to the point where he 
finally agreed to be evaluated. 
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Figure 2:  Color photos of a large, 12 cm diameter, necrotic basal cell carcinoma involving the 
left side of the nose, the medial eyelids, and lacrimal apparatus.  
   
  Uncorrected visual acuities were 20/400 OD and 20/200 OS.  The pupils were 
round, regular, and reactive, with no afferent defect, and there was a full range of 
ocular motility without restriction.  An adequate refraction could not be completed 
due to the size of the tumor and poor response from the patient.  Examination of 
ophthalmic structures was difficult due to physical obstruction by the tumor; what 
could be seen of the fundus on dilated exam was grossly intact OU, with advanced 
nuclear cataracts OU further restricting internal examination.  
   
  Three months after his initial presentation, the patient agreed to undergo a surgical 
resection of the tumor at another VA facility.  A wide local excision with eyelid 
reconstruction and skin grafts was successfully accomplished under general 
anesthesia, with frozen section margins determined to be tumor-free.  While the 
cancer was estimated to have invaded 50% of the lower eyelid and 25% of the upper 
eyelid, the eye itself was able to be preserved; however, the lacrimal canaliculi were 
involved with the tumor and removed during the surgery.  The final skin defect on 
the nasal dorsum measured 5.5 cm x 4.5 cm.    
   
  A 2-month post-operative examination at the Eye Clinic showed significant 
residual medial ectropion of the left lower lid, loss of the left lower punctum with 
chronic epiphora, and partial left upper lid ptosis (Figure 3).  Ophthalmic 
examination was considerably easier at this stage, and the patient’s affect was much 
improved.  A refraction found -10.00 DS OD and -0.50 DS OS, with best corrected 
distance acuities of 20/400 OD and 20/150 OS.  Based on the refractive 
anisometropia and the patient’s history of longstanding decreased vision since 
childhood in that eye, a diagnosis of refractive amblyopia OD was made.  The 
dilated fundus examination was unremarkable, while slit lamp evaluation was 
significant for grade 3+ nuclear cataracts OU.   
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Figure 3:  Post-operative color photo showing the patient after a wide surgical excision of the 
basal cell carcinoma with skin graft and eyelid reconstruction. 
   
  Cataract surgery was recommended, but the patient declined any further surgical 
intervention.  Glasses and low vision aids were offered, which he also refused, 
stating that his vision was good enough for his needs.  The patient continued to be 
followed periodically without recurrence of the tumor, and he passed away seven 




  Basal cell carcinoma is the most common cutaneous tumor in humans, accounting 
for 80% of all nonmelanoma skin cancers, and is the most frequent cancer of the 
eyelid.1-3 It arises from the neoplastic proliferation of basal cells in the epidermis 
of the skin, which can then invade the dermal layer and surrounding tissue.  Since 
ultraviolet (UV) exposure is a known primary risk factor, these tumors 
characteristically develop on areas of the body which are exposed to the sun, with 
80% developing on the head and neck, including the eyelids.3  There is also a 
geographic and occupational correlation as the incidence of BCC is higher with 
closer proximity to the equator and in workers with outdoor jobs due to increased 
UV exposure.4  Other risk factors for BCC include phenotypic traits such as fair 
skin or light colored hair, use of tanning beds, immunosuppression, trauma such as 
burns leading to cutaneous scarring, smoking, and exposure to environmental 
contaminants such as arsenic, coal tar, and ionizing radiation.1,3,5 Periocular BCC 
is more commonly found on the lower eyelid (44%-56%), followed by the medial 
canthus (27%-37%), upper eyelid (8%-9%), and lateral canthus (6%-8%).6,7  Eyelid 
BCC is more prevalent in older adults in their sixth to eighth decade of life, but up 
to 15% may develop in children or young adults.8   
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  Clinically, periocular BCC typically manifests initially as asymptomatic or mildly 
symptomatic eyelid lesions, with slow growth and minimal invasion of adjacent 
tissue. Metastasis is extremely rare, with incidence rates reported from 0.0028% to 
0.55% of all BCCs, depending on the size, location, and histological subtype.9,10 
While several clinical and histological subtypes have been described, the most 
common morphological form is nodular, accounting for 50% – 79% of all BCC 
presentations.1,11   Nodular BCC manifests with pearly, shiny papules or nodules 
with branching telangiectasias.  As it grows, crusting may appear overlying a 
central depression, and over time this depression may ulcerate, which has 
sometimes been referred to as a “rodent” ulcer.3 Bleeding of the lesion is common 
with minor trauma.  Superficial BCC is the second most common clinical subtype 
(up to 15% of cases), typically appearing as a well circumscribed, scaly, thin 
reddish macule or plaque.1 Nodular and superficial subtypes tend to be less 
aggressive in their clinical course.  Morpheaform (sclerosing, infiltrative) is the 
least common presentation but the most aggressive form, occurring in 5% - 10% of 
cases.  Lesions are pink to white in color, with a shiny, smooth, scar-like 
appearance, possibly with indurated plaques, crusting and erosions, and indistinct 
margins.1 Because of this variability in presentation, BCC may be difficult to 
diagnose from clinical appearance alone; a wide range from 10%-40% of periocular 
BCCs are reported to be initially misdiagnosed.3,6,12  A biopsy is therefore 
recommended to ensure accurate identification of growths which are suspicious for 
malignancy.12  
   
  Several medical therapies for BCC have been proposed, including radiation 
therapy, cryotherapy, carbon dioxide laser, photodynamic therapy, and 
pharmacologic agents such as intralesional interferon or topical imiquimod, but 
these methods are associated with higher rates of recurrence.13 The treatment of 
choice for periocular  BCC is surgical excision with microscopic monitoring of the 
excision margins, either using a wide surgical excision with frozen section or 
paraffin margin control, or with a Mohs micrographic surgery technique.4,13,14 
Standard excision without intraoperative histological margin monitoring may be 
appropriate for some cases of smaller nodular tumors where the clinical margins 
can be defined with reasonable accuracy.  The primary goal is to remove the tumor 
along with an adequate margin of normal surrounding skin to ensure complete 
clearance of cancerous cells and reduce the risk of recurrence, while trying to 
preserve function and cosmesis at the surgical site.13-15 Surgical cure rates without 
recurrence for periocular BCC are reported as high as 95%.7,13-15  A Mohs technique 
has been suggested to be the preferred method for periocular BCC excision to 
minimize the loss of normal tissue and achieve the best functional and cosmetic 
results around the eyelids with the lowest recurrence rate; however, it is generally 
considered more expensive and is not available in every setting.7,16,17  A Cochrane 
literature review comparing these surgical techniques though could not 
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conclusively confirm that Mohs procedures had a clear advantage in recurrence or 
complication rate compared to standard surgical excision with wide margins, and 
also did not find any direct cost comparison of the different techniques.18 
Management decisions should be individualized based on the clinical presentation, 
patient risk factors, and surgeon’s expertise in each setting.  
   
  More aggressive or neglected periocular BCC can result in orbital and intracranial 
invasion, an uncommon complication occurring in less than 5% of cases.19 Signs 
that suggest orbital involvement include a visible or palpable mass fixed to the 
bone, limitation of ocular motility, and globe displacement.  If left unchecked, 
posterior extension into the orbital apex and cavernous sinus may occur.  
Longstanding neglected tumors, recurrent or incompletely excised tumors, and 
medial canthus location are risk factors for orbital and intracranial extension.19,20 
Radiologic imaging is necessary in cases of suspected orbital involvement to 
determine the extent of the infiltration, with computed tomography (CT) to look for 
bony destruction and magnetic resonance imaging (MRI) to demonstrate soft tissue 
changes.  Management of more extensive orbital invasion often requires 
exenteration with or without adjunctive radiotherapy to achieve local control of the 
tumor.19,20 In selected cases of anterior orbital involvement or with monocular 
patients, local resection of the tumor may still be an option.    
   
  In patients with more locally advanced or metastatic BCC, or in cases of basal cell 
nevus syndrome (Gorlin syndrome) which involves numerous periocular and facial 
cutaneous tumors, the condition may not be amenable to surgery or radiotherapy.21  
Vismodegib and sonidegib are oral Hedgehog signaling pathway inhibitors that 
have had some success in shrinking the tumor size.22-24 (The Hedgehog signaling 
pathway is critical for cellular differentiation during fetal development, with 
limited activity beyond this stage.)  Anomalous activation of the Hedgehog 
pathway has been implicated in several types of malignancies including BCC.  In a 
study of seven recurrent, locally advanced cases of periocular BCC without 
metastasis that were not good candidates for surgical resection or radiation, more 
than half which were treated with vismodegib showed clinically significant 
shrinkage of the tumor which was sustained for at least six months.24 Emerging 
clinical trial data will continue to better define the role of this medical therapy for 
selected patients who are not good candidates for other treatment modalities.      
   
  Early identification and treatment of suspicious lesions is important to improve 
the outcome and lessen the chance of complications from more aggressive tumor 
growth.  It is rare for a BCC to progress to this size and show the degree of localized 
invasion and destruction of contiguous tissue seen in this patient.  However, 
instances of significant BCC growth with extensive localized morbidity and 
disfigurement are occasionally reported from longstanding neglected tumors.25-32 
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There is likely a complex interaction of individual psychological and 
socioeconomic risk factors that leads to a situation of neglect and allows these 
lesions to progress to such advanced stages.  Older age, lower socioeconomic status, 
mistrust or fear of the medical system, mental illness, and lack of education 
concerning the significance of the diagnosis are some proposed influences that may 
contribute to the delay in seeking medical attention for skin cancers.26,27,32 It is also 
possible that a slow growing, asymptomatic neoplasm may not initially cause 
concern, and the patient can react to subsequent growth with denial of the problem 
or an acceptance of a slowly progressive situation without understanding its clinical 
significance.  The patient’s decision to seek medical treatment may be ultimately 
influenced by external factors such as a sudden change in the tumor (like bleeding, 
pain, or rapid growth), or the proactive intervention of a friend or family 
member.25,27  A multidisciplinary approach may be needed to address these barriers 





  BCC is generally a slow growing, indolent tumor which usually carries a high cure 
rate with appropriate surgical techniques.  However, delays in diagnosis or in 
seeking medical care with more aggressive forms of BCC can lead to extensive 
localized tissue destruction, cosmetic disfigurement, and functional disability.  
Cases of extreme tumor neglect are rare and may require more complex 
intervention with extensive reconstructive efforts. Understanding and overcoming 
the multiple psychosocial factors which manifest in denial and delayed care can be 
challenging.  This case is a reminder of the importance of early recognition and 
intervention to prevent significant morbidity.     
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